

**FAX**

GlaxoSmithKline

To M/S Issue Fee, Attn: Examiner B. Robinson, Art Unit
1625

Company USPTO

Fax 703-746-4000

From Valerie L. Phillips

Tel 919-483-8223 Fax 919-483-6730

E-mail Vlp47157@gsk.com

Date September 17, 2003 Pages including cover 10

Subject Request for Clarification

Glaxo Wellcome Inc.
PO Box 13398
Five Moore Drive
Research Triangle Park
North Carolina 27709
Tel: 919 483 2100
www.gsk.com

Serial No.: 09/830,836

Filing Date: May 1, 2001

Applicant: Campbell et al.

Title: Pyrazolopyridine Derivatives as Selective COX-2 Inhibitors

Attached:

Certificate of transmission via facsimile

Request for Clarification Filed Pursuant to 37 CFR 1.312

Copy: Post Office Receipt w/postcard, IDS, PTO1449, International Search Report

Thank you,
Valerie Phillips

Certificate of Transmission by Facsimile (37 CFR 1.8)

I hereby certify that this Response to Office Action is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. 703-746-4000) on September 17, 2003.

Valerie L. Phillips
Valerie L. Phillips

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

PG3602USw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Campbell, et al

Serial No.: 09/830,836

Examiner: B. Robinson

Filing Date: 1 May 2001

Art Unit: 1625

For: PYRAZOLOPYRIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS

Box Issue Fee

Director of the United States Patent and Trademark Office

P.O. Box 1450

Alexandria, Virginia 22313-1450

Fax: (703) 746-4000

Request for Clarification Filed Pursuant to 37 CFR 1.312

Sir:

Further to the Notice of Allowance mailed 29 July 2003, Applicants respectfully request clarification of the record with respect to the following matter.

Applicants timely filed an IDS and PTO-1449 together with the application on 1 May 2001 for which the initialed PTO-1449 has not been returned. A copy of the IDS and PTO-1449 and the stamped postcard indicating receipt by the PTO is attached. The PTO-1449 listed documents which were identified on the PCT Search report, a copy of which was also filed with the application. Accordingly, copies of the references were not provided separately by Applicants. Applicants respectfully request that an initialed copy of the PTO-1449 submitted 1 May 2001, indicating that the cited references have been considered, be returned to Applicants prior to the grant of the patent.



SEP. 17. 2003 11:42AM

GW GLOBAL R&D IS

NO. 7570 P. 3

PG3602USw

The Examiner is invited to contact the undersigned at (919) 483-8222, if Applicants can further facilitate the Examiner's resolution of these matters.



Respectfully submitted,

A handwritten signature in black ink, appearing to read "L. Morgan", written over a horizontal line.

Lorie Ann Morgan
Attorney for Applicants
Registration No. 38,181

Date: 16 September, 2003
GlaxoSmithKline
Five Moore Drive, PO Box 13398
Research Triangle Park
North Carolina 27709
(919) 483-8222
Fax: (919) 483-7988